Using Plasma Levels to Improve Antipsychotic Treatment in Schizophrenia
The article explains how therapeutic drug monitoring can reduce guesswork in antipsychotic care for schizophrenia. It can help detect nonadherence, guide dose targets, and define response thresholds. The discussion also covers the concept of a 'point of futility' in treatment decisions.
Therapeutic drug monitoring uses plasma levels of antipsychotic medication to inform schizophrenia treatment. Rather than relying only on observation and guesswork, clinicians can use these measurements to make care more precise.
The approach may help identify when medication is not being taken as prescribed, support appropriate dose targets, and clarify response thresholds. The article also discusses a point of futility in treatment decisions, when further changes may no longer be useful.
For people with schizophrenia and their families, clearer medication monitoring could mean fewer prolonged trials and more informed conversations with clinicians. It may also help health systems use antipsychotic treatment more efficiently, though access, cost, and implementation could shape who benefits. The concept of a point of futility may influence how care teams discuss continuing or changing treatment, but such decisions remain clinical and individual.